Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026

robot
Abstract generation in progress

Prelude Therapeutics announced preclinical data for PRT13722, a first-in-class, orally bioavailable KAT6A degrader for HR+/HER2- breast cancer. The data show potential for differentiated efficacy and safety, including complete responses as monotherapy in various models. Prelude aims to file an Investigational New Drug (IND) application by mid-2026 and initiate a clinical trial in the second half of 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin